Improving Outcomes for Patients with Myelofibrosis: A Case-based Analysis

Three JAK inhibitors are now approved for the treatment of intermediate- to high-risk MF with trials demonstrating improvement in spleen volume, disease symptoms, and quality of life. However, at the same time, data shows that there is a high frequency of discontinuation because of either adverse events or, more frequently, progressive disease that lead to poor outcomes with survival after ruxolitinib discontinuation. The faculty will review the clinical practice considerations for the use of new second-line therapies for the treatment of myelofibrosis and touch on data emerging from clinical trials in the second-line setting. In this presentation, Dr. Mascarenhas and Dr. Kurtin review a series of case scenarios to demonstrate selecting the most appropriate treatment for specific patient populations from the available options. Additionally, these experts share recommendations for shared decision-making and the importance of patient education.